Cargando…

DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis. METHODS: Methylome data, generated using 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Ankita, Bararia, Akash, Ganguly, Debopriyo, Mondal, Pronoy Kanti, Roy, Paromita, Banerjee, Sudeep, Ghosh, Shibajyoti, Gulati, Sumit, Ghatak, Supriyo, Chattopadhay, Bitan Kumar, Basu, Priyadarshi, Chatterjee, Aniruddha, Sikdar, Nilabja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635159/
https://www.ncbi.nlm.nih.gov/pubmed/36329447
http://dx.doi.org/10.1186/s12935-022-02737-1
_version_ 1784824648729362432
author Chatterjee, Ankita
Bararia, Akash
Ganguly, Debopriyo
Mondal, Pronoy Kanti
Roy, Paromita
Banerjee, Sudeep
Ghosh, Shibajyoti
Gulati, Sumit
Ghatak, Supriyo
Chattopadhay, Bitan Kumar
Basu, Priyadarshi
Chatterjee, Aniruddha
Sikdar, Nilabja
author_facet Chatterjee, Ankita
Bararia, Akash
Ganguly, Debopriyo
Mondal, Pronoy Kanti
Roy, Paromita
Banerjee, Sudeep
Ghosh, Shibajyoti
Gulati, Sumit
Ghatak, Supriyo
Chattopadhay, Bitan Kumar
Basu, Priyadarshi
Chatterjee, Aniruddha
Sikdar, Nilabja
author_sort Chatterjee, Ankita
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis. METHODS: Methylome data, generated using 450 K bead array, was compared between paired PDAC and normal samples in the TCGA cohort (n = 9) and our Indian cohort (n = 7). The total Indian Cohort (n = 75) was split into cohort 1 (n = 7), cohort 2 (n = 22), cohort 3 (n = 26) and cohort 4 (n = 20).Validation of differential methylation (6 selected CpG loci) and associated gene expression for differentially methylated genes (10 selected gDMs) were carried out in separate validation cohorts, using MSP, RT-PCR and IHC correlations between methylation and gene expression were observed in TCGA, GTEx cohorts and in validation cohorts. Kaplan–Meier survival analysis was done to study differential prognosis, during 2–5 years of follow-up. RESULTS: We identified 156 DMPs, mapped to 91 genes (gDMs), in PDAC; 68 (43.5%) DMPs were found to be differentially methylated both in TCGA cohort and our cohort, with significant concordance at hypo- and hyper-methylated loci. Enrichments of “regulation of ion transport”, “Interferon alpha/beta signalling”, “morphogenesis and development” and “transcriptional dysregulation” pathways were observed among 91 gDMs. Hyper-methylation of NPY and FAIM2 genes with down-regulated expression in PDAC, were significantly associated with poor prognosis in the Indian patient cohort. CONCLUSIONS: Ethnic variations among populations may determine the altered epigenetic landscape in the PDAC patients of the Indian cohort. Our study identified novel differentially methylated genes (mainly NPY and FAIM2) and also validated the previously identified differentially methylated CpG sites associated with PDAC cancer patient’s survival. Comparative analysis of our data with TCGA and CPTAC cohorts showed that both NPY and FAIM2 hyper-methylation and down-regulations can be novel epigenetically regulated genes in the Indian patient population, statistically significantly associated with poor survival and advanced tumour stages. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02737-1.
format Online
Article
Text
id pubmed-9635159
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96351592022-11-05 DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort Chatterjee, Ankita Bararia, Akash Ganguly, Debopriyo Mondal, Pronoy Kanti Roy, Paromita Banerjee, Sudeep Ghosh, Shibajyoti Gulati, Sumit Ghatak, Supriyo Chattopadhay, Bitan Kumar Basu, Priyadarshi Chatterjee, Aniruddha Sikdar, Nilabja Cancer Cell Int Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis. METHODS: Methylome data, generated using 450 K bead array, was compared between paired PDAC and normal samples in the TCGA cohort (n = 9) and our Indian cohort (n = 7). The total Indian Cohort (n = 75) was split into cohort 1 (n = 7), cohort 2 (n = 22), cohort 3 (n = 26) and cohort 4 (n = 20).Validation of differential methylation (6 selected CpG loci) and associated gene expression for differentially methylated genes (10 selected gDMs) were carried out in separate validation cohorts, using MSP, RT-PCR and IHC correlations between methylation and gene expression were observed in TCGA, GTEx cohorts and in validation cohorts. Kaplan–Meier survival analysis was done to study differential prognosis, during 2–5 years of follow-up. RESULTS: We identified 156 DMPs, mapped to 91 genes (gDMs), in PDAC; 68 (43.5%) DMPs were found to be differentially methylated both in TCGA cohort and our cohort, with significant concordance at hypo- and hyper-methylated loci. Enrichments of “regulation of ion transport”, “Interferon alpha/beta signalling”, “morphogenesis and development” and “transcriptional dysregulation” pathways were observed among 91 gDMs. Hyper-methylation of NPY and FAIM2 genes with down-regulated expression in PDAC, were significantly associated with poor prognosis in the Indian patient cohort. CONCLUSIONS: Ethnic variations among populations may determine the altered epigenetic landscape in the PDAC patients of the Indian cohort. Our study identified novel differentially methylated genes (mainly NPY and FAIM2) and also validated the previously identified differentially methylated CpG sites associated with PDAC cancer patient’s survival. Comparative analysis of our data with TCGA and CPTAC cohorts showed that both NPY and FAIM2 hyper-methylation and down-regulations can be novel epigenetically regulated genes in the Indian patient population, statistically significantly associated with poor survival and advanced tumour stages. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02737-1. BioMed Central 2022-11-03 /pmc/articles/PMC9635159/ /pubmed/36329447 http://dx.doi.org/10.1186/s12935-022-02737-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chatterjee, Ankita
Bararia, Akash
Ganguly, Debopriyo
Mondal, Pronoy Kanti
Roy, Paromita
Banerjee, Sudeep
Ghosh, Shibajyoti
Gulati, Sumit
Ghatak, Supriyo
Chattopadhay, Bitan Kumar
Basu, Priyadarshi
Chatterjee, Aniruddha
Sikdar, Nilabja
DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort
title DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort
title_full DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort
title_fullStr DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort
title_full_unstemmed DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort
title_short DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort
title_sort dna methylome in pancreatic cancer identified novel promoter hyper-methylation in npy and faim2 genes associated with poor prognosis in indian patient cohort
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635159/
https://www.ncbi.nlm.nih.gov/pubmed/36329447
http://dx.doi.org/10.1186/s12935-022-02737-1
work_keys_str_mv AT chatterjeeankita dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT barariaakash dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT gangulydebopriyo dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT mondalpronoykanti dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT royparomita dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT banerjeesudeep dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT ghoshshibajyoti dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT gulatisumit dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT ghataksupriyo dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT chattopadhaybitankumar dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT basupriyadarshi dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT chatterjeeaniruddha dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort
AT sikdarnilabja dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort